10月21日，安进盘中上涨3.04%，报437.85美元，成交额6.01亿美元。
消息面上，安进与阿斯利康公布Tezspire在嗜酸性粒细胞性食管炎三期CROSSING试验中取得统计学显著且具临床意义的改善，带动股价走强。
具体看，24周时210mg与420mg剂量组组织学缓解率分别为64.8%和68.9%，显著高于安慰剂组的3.5%；吞咽困难症状评分分别改善18.8分和22分，安慰剂组为14.7分，且疗效持续至52周。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.